For the primary objective and the first secondary objectives of the present study, patients were eligible if they had at least one histological report with HR or HER2 status on primary tumour and at least one histological report with HR or HER2 status on a metastasis within the first 6 months of MBC diagnosis, before any disease progression (main study population). For the other secondary objective, patients were included if they had histological reports and HR or HER2 status on primary tumour and metastasis within 6 months from the first progression of MBC (second study population).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.